ESMO 2022 Conference Coverage

 

ESMO 2022 Conference Coverage
J

ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase II Trial: Avelumab vs. Standard 2L Treatment Chemo in mCRC Patients With Microsatellite Instability

By ESMO 2022 Conference Coverage FEATURING Julien Taieb
By ESMO 2022 Conference Coverage FEATURING Julien Taieb
206 views
September 15, 2022
0 Comments
Login to view comments. Click here to Login
GI
07:10
ESMO 2022 Conference Coverage

ESMO 2022 on ctDNA Dynamics, CEA, and Sites of Recurrence for the Ra…

Feat. J. Tie
01:21
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on Characterizing the Clinico-Genomic La…

Feat. F. Keane
05:27
ESMO 2022 Conference Coverage

ESMO 2022 on Characterizing the Clinico-Genomic Landscape and Outcom…

Feat. F. Keane
01:01
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the NuTide:302 Study: NUC-3373, a Pro…

Feat. A. Coveler
04:14
ESMO 2022 Conference Coverage

ESMO 2022 on the NuTide:302 Study: NUC-3373, a ProTide Transformatio…

Feat. A. Coveler
09:14
ESMO 2022 Conference Coverage

ESMO 2022 on the Global Phase 3 Multiregional Clinical Trial FRESCO-…

Feat. A. Dasari
06:14
ESMO 2022 Conference Coverage

ESMO 2022 on the Phase 3 HIMALAYA Study: Impact of Viral Aetiology o…

Feat. S. L. Chan
12:50
ESMO 2022 Conference Coverage

ESMO 2022 on KRYSTAL-1: Updated Efficacy & Safety of Adagrasib W…

Feat. S. Klempner
43
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Global Phase 3 Multiregional Clin…

Feat. A. Dasari
42
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Updated Analysis of DESTINY-Gastr…

Feat. G. Ku
05:29
ESMO 2022 Conference Coverage

ESMO 2022 Updated Analysis of DESTINY-Gastric02 Trial: T-DXd in West…

Feat. G. Ku
01:26
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Ce…

Feat. A. Orlandi
12:14
ESMO 2022 Conference Coverage

ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Cetuximab vs. FOLFIR…

Feat. A. Orlandi
03:47
ESMO 2022 Conference Coverage

ESMO 2022: Early Decreases in KRAS Mutant Allele Frequency Predicts …

Feat. H. Lenz
01:35
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022: Beyond 1L for mCRC - Best Practices and…

Feat. T. Price
20:07
Timothy Price

Beyond 1L for mCRC - Best Practices and Practical Nuances

16:12
ESMO 2022 Conference Coverage

ESMO 2022 on Advances in HER2-Targeted Therapy or Novel Targeted The…

Feat. K. Shitara
18
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022: Real-World Monitoring of ctDNA Reliably…

Feat. S. Cohen
05:42
ESMO 2022 Conference Coverage

ESMO 2022: Real-World Monitoring of ctDNA Reliably Predicts Cancer R…

Feat. S. Cohen
09:24
ESMO 2022 Conference Coverage

ESMO 2022 Final Analysis of the Randomized, Phase 3 RATIONALE-301 St…

Feat. M. Kudo
04:44
ESMO 2022 Conference Coverage

ESMO 2022 on the Updated OS From the Phase 3 TOPAZ-1 Study: Durvalum…

Feat. D. Oh
46
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: …

Feat. J. Edeline
04:28
ESMO 2022 Conference Coverage

ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: Pembrolizumab vs. …

Feat. J. Edeline
13:16
ESMO 2022 Conference Coverage

ESMO 2022 on the NICHE-2 Study: Neoadjuvant Immune Checkpoint Inhibi…

Feat. M. Chalabi
19
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the HIPECT4 Randomized Phase 3 Study:…

Feat. A. Arjona-Sanchez
05:02
ESMO 2022 Conference Coverage

ESMO 2022 on the HIPECT4 Randomized Phase 3 Study: Adjuvant Hyperthe…

Feat. A. Arjona-Sanchez
22
ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase…

Feat. J. Taieb
06:19
ESMO 2022 Conference Coverage

ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase II Trial: Aveluma…

Feat. J. Taieb